MediGene chronicles

MediGene chroniclesSelected events tracked against MediGene’s weekly stock price (FSE:MDG). Y-axis = logarithmic scale A. 6/30/00 - Raises E125.4M ($117.4M) in an IPO. At that time, MDG was focused on developing therapeutics for cardiovascular and cancer indications. Lead programs included Etomoxir, about to start Phase II testing for congestive heart failure (CHF); and Polyphenon E, in Phase II for genital warts.

B. 1/12/01 - Acquires the 91% ofNeuroVirit doesn’t already own for about E53M ($50M) in stock. NeuroVir specializes in herpes simplex virus vectors to treat cancer. MDG gets NV-1020, which is now in Phase I/II for liver metastases, and G207, now in Phase I for glioblastoma multiforme...